OmegaGenesis- Based on the newly discovered angiogenic properties of inorganic nanorod materials

[Jacob]

http://www.omegagenesis.com/resources/p ... Growth.pdf

Mice pics towards the bottom..

OmegaGenesis is developing a nanotechnology solution to treat hair loss resulting from natural or
medically induced causes. Based on the newly discovered angiogenic properties of inorganic nanorod
materials, we are developing a topical product to treat hair loss. The product enhances blood supply to
hair follicle, stimulates the hair roots and invigorates the growth cycle of hair.
A topical cream or gel will be applied to the scalp similar to other topical hair loss treatments. The
nanorods are a size that allows penetration into the follicle cavity thereby allowing absorption in the
dermal papilla. Data have shown both para- and intracellular transport of the nanorods indicating good
percutaneous permeability characteristics.
Our product will dispensed by a dropper, from a collapsible laminated tube or metered dose pump as
needed to ensure consistent application rates and dosing schedule.
Application and Patient Benefit
A topical product is under development for use in hair loss. The product will be applied on a routine
basis over several weeks to months to stimulate new hair growth through follicle restoration. The
product may be used for an indefinite period to maintain hair growth for patients with androgenic
alopecia, a progressive condition.
Once perifollicular vascularization has been stimulated, we anticipate a lower maintenance dose to
reverse the effects of follicle shrinking. Further benefits may include accelerated hair regrowth and
increased size of hair follicles and hair shafts.

OmegaGenesis developed a
nanotechnology method that externally
modulates blood supply to hair roots using
inorganic nanomaterials. To our knowledge, this
is the first nanotechnology product which works
locally to increase the active phase of hair
growth cycle without affecting regular blood
pressure or causing allergenic reactions.

The planned stages are:
• Pilot study completed and observed hair growth
• Material synthesis and formulation in progress for phase 2 pilot study – June, 2009
• Final Animal trials starts September 1, 2009
• Clinical trial proposed for February 1, 2010

[Jacob]

Another page on it:

http://www.omegagenesis.com/resources/p ... ay2009.pdf

[Jacob]

OmegaGenesis has developed novel methods to safely generate large-scale quantities of the nano-scale europium europium hydroxide rods, which were first developed at the Mayo Clinic and shown to promote angiogenesis , the formation of new blood vessels. The company has established non-toxicity of the europium hydroxide nanorods in lab testing for human applications and pre-clinical studies for use of the nanorods in the treatment of wound healing, diabetic foot ulcers and hair growth are underway

http://www.thefreelibrary.com/OmegaGene ... 0190658055

Oostur Raza, Co-Founder, President and CEO of OmegaGenesis has over 40 years of engineering, technology, business and executive experience. Oostur's management roles include: General Electric, Fujitsu , Adobe, Sun Microsystems, and a variety of other technology companies. Oostur started his career as a Nuclear Engineer with General Electric where he designed nuclear plant fuel and cores and worked with rare earth elements. He is the recipient GE Thomas Edison Award and has a MS in Nuclear Engineering from the University of Wisconsin.

Salah Sedarous Ph.D. is Chief Technology Officer and Co-founder of OmegaGenesis. Salah leads OmegaGenesis research and development efforts and coordinates the Company's work with the Mayo Clinic research team. Previous experience includes: Chief Scientist for Pemstar, Inc., Research Scientist & Fellow, Biochemistry and Molecular Biology at the Mayo Clinic for 13 years. Salah received his Ph.D. in Physics, North Dakota State University, and MBA in Management, University of Saint Thomas.

http://www.omegagenesis.com/html/Management.html

[Swimmy]

Sounds interesting. Different and New. Something definitely to watch

[georgex6]

so when this hit the market 2013???

[Jacob]

According to the info in the first link it says approval in 2012..so I would think then or 2013. Of course these things never seem to get released on time.

BTW georgex6..welcome to HLF. Would it be possible to have a link to here from your website(if you don't already)- which I think is ok for you to post since it's a little hard for most of us to read Thanks

[Jacob]

Got a response from them:

We are working through our pre-clinical studies and results to date have shown
hair growth in animal models. We are. developing two drug assets. The other one
is for amputation prevention.

We are currently raising next round of funding to execute on clinical trials on both
drug assets. We will continue to update our schedule as we execute. So stay tuned.

[georgex6]

sorry jacob but i didnt understand what you meant about the link

[Jacob]

Check your messages/pm's

[Bombarie]

Very very interesting!!!!
Keep this tread alive:)